Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$4.13
-0.2%
$3.47
$2.76
$13.11
$225.24M-1.5663,666 shs449,223 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.65
$7.06
$3.85
$8.98
$614.79M1.25665,612 shs513,206 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.96
-1.4%
$10.70
$6.73
$12.61
$761.20M0.024,439 shs23,035 shs
Urogen Pharma stock logo
URGN
Urogen Pharma
$19.40
+1.8%
$12.52
$3.42
$19.74
$880.60M1.121.24 million shs1.01 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-0.24%+6.44%+25.91%-10.02%-66.42%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%-8.60%+10.55%+5.52%+46.27%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-1.35%+6.82%+2.91%+21.52%+28.19%
Urogen Pharma stock logo
URGN
Urogen Pharma
+1.78%+2.37%+49.69%+68.55%+17.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
3.0993 of 5 stars
3.60.00.00.01.93.31.3
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.145 of 5 stars
3.53.00.04.81.12.50.6
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.0013 of 5 stars
3.55.00.00.03.20.00.6
Urogen Pharma stock logo
URGN
Urogen Pharma
4.6169 of 5 stars
4.54.00.04.52.42.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.14
Buy$19.80379.42% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00213.73% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00173.72% Upside
Urogen Pharma stock logo
URGN
Urogen Pharma
3.00
Buy$32.8669.37% Upside

Current Analyst Ratings Breakdown

Latest ALMS, PHAR, URGN, and MGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$17.00
7/25/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00
7/8/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
7/7/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
6/16/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$50.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetNeutral ➝ Neutral$16.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Buy$31.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$23.00 ➝ $47.00
6/13/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $30.00
6/12/2025
Urogen Pharma stock logo
URGN
Urogen Pharma
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/A$5.51 per shareN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M18.47N/AN/A$0.87 per share8.79
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.53$0.07 per share149.88$3.25 per share3.37
Urogen Pharma stock logo
URGN
Urogen Pharma
$90.40M9.91N/AN/A($0.21) per share-92.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
-$294.23MN/A0.00N/AN/AN/A-406.27%-107.29%8/12/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A20.13N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.13N/A365.33N/A-2.19%-3.38%-1.82%N/A
Urogen Pharma stock logo
URGN
Urogen Pharma
-$126.87M-$3.18N/AN/AN/A-150.68%-97,487.15%-49.57%8/7/2025 (Estimated)

Latest ALMS, PHAR, URGN, and MGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.11N/AN/AN/A$1.80 millionN/A
8/11/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52N/AN/AN/A$8.00 millionN/A
8/7/2025Q2 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.85N/AN/AN/A$23.06 millionN/A
7/31/2025Q2 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.10$0.06+$0.16$0.06$70.36 million$93.20 million
5/14/2025Q1 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.47-$1.82-$0.35-$1.82N/AN/A
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
5/12/2025Q1 2025
Urogen Pharma stock logo
URGN
Urogen Pharma
-$0.83-$0.92-$0.09-$0.92$22.71 million$20.25 million
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Urogen Pharma stock logo
URGN
Urogen Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
3.73
3.73
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00
Urogen Pharma stock logo
URGN
Urogen Pharma
N/A
5.65
5.47

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
Urogen Pharma stock logo
URGN
Urogen Pharma
91.29%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
40.70%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
Urogen Pharma stock logo
URGN
Urogen Pharma
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A54.41 million32.26 millionN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.36 million74.34 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.51 million67.10 millionNot Optionable
Urogen Pharma stock logo
URGN
Urogen Pharma
20046.20 million43.85 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alumis stock logo

Alumis NASDAQ:ALMS

$4.13 -0.01 (-0.24%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.16 +0.04 (+0.85%)
As of 08/1/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$7.65 0.00 (0.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.65 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.96 -0.15 (-1.35%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$10.99 +0.03 (+0.26%)
As of 08/1/2025 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Urogen Pharma stock logo

Urogen Pharma NASDAQ:URGN

$19.40 +0.34 (+1.78%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$19.44 +0.04 (+0.21%)
As of 08/1/2025 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.